Myths vs facts: CYP2C19 and longevity

CYP2C19 is primarily a drug-metabolizing enzyme, best known for its role in processing clopidogrel and certain antidepressants. Claims that CYP2C19 variants directly influence longevity are not supported by robust evidence. While some indirect links exist (e.g., poor metabolizers may have altered cardiovascular outcomes), these are not sufficient to establish a causal effect on lifespan. Consumer DNA tests, including MyBody-X, do not provide validated pharmacogenetic analysis for CYP2C19. The evidence is mixed to unclear. Be cautious of longevity claims: such tests are not clinically actionable for predicting lifespan and should not be used without professional medical guidance.